Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin‐C and bacillus Calmette‐Guérin in patients with high‐risk bladder cancer

To report the 10‐year follow‐up of a study randomizing between instillations of bacillus Calmette‐Guérin (BCG) and mitomycin‐C (MMC) for treating high‐risk and not muscle‐invasive urinary bladder cancer to assess progression, the need for more aggressive treatment and survival (cancer‐specific and overall), as many of the published studies comparing different treatments for disease that is not muscle‐invasive have a short follow‐up.

[1]  H. Woo,et al.  Management of stage T1 tumors of the bladder: International Consensus Panel. , 2005, Urology.

[2]  B. Kupelnick,et al.  The Influence of Intravesical Therapy on Progression of Superficial Transitional Cell Carcinoma of the Bladder: A Metaanalytic Comparison of Chemotherapy versus Bacilli Calmette-Guerin Immunotherapy , 2004, American journal of clinical oncology.

[3]  T. Wilt,et al.  Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials , 2004, BJU international.

[4]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[5]  Gerhard Jakse,et al.  Guidelines on bladder cancer. , 2002, European urology.

[6]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[7]  J. Chin,et al.  Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. , 2001, Journal of the National Cancer Institute.

[8]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[9]  J. Montie,et al.  Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. , 1999, The Journal of urology.

[10]  B. Norlén,et al.  5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.

[11]  B. Norlén,et al.  A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. , 1996, The Journal of urology.